KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 8.19%.

  • Castle Biosciences' EBIT Margin fell 141100.0% to 8.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.17%, marking a year-over-year decrease of 98400.0%. This contributed to the annual value of 2.61% for FY2024, which is 335400.0% up from last year.
  • Latest data reveals that Castle Biosciences reported EBIT Margin of 8.19% as of Q3 2025, which was down 141100.0% from 4.93% recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' EBIT Margin ranged from a high of 5.92% in Q3 2024 and a low of 91.3% during Q1 2022
  • Over the past 5 years, Castle Biosciences' median EBIT Margin value was 18.78% (recorded in 2021), while the average stood at 29.8%.
  • In the last 5 years, Castle Biosciences' EBIT Margin tumbled by -725200bps in 2022 and then soared by 674900bps in 2024.
  • Over the past 5 years, Castle Biosciences' EBIT Margin (Quarter) stood at 60.59% in 2021, then rose by 2bps to 59.55% in 2022, then surged by 86bps to 8.56% in 2023, then skyrocketed by 155bps to 4.69% in 2024, then crashed by -275bps to 8.19% in 2025.
  • Its last three reported values are 8.19% in Q3 2025, 4.93% for Q2 2025, and 31.74% during Q1 2025.